Windtree Therapeutics (WINT) announced that it has filed a new istaroxime PCT patent application entitled, “ISTAROXIME DERIVATIVES THEREOF FOR PREVENTING OR REDUCING THE RISK OF ACUTE MYOCARDIAL ARRHYTHMIA.” The patent filing expands upon data obtained from animal model testing and the istaroxime human clinical trials in acute heart failure and early cardiogenic shock, including the latest positive Phase 2b istaroxime study in ECS patients. Istaroxime has also shown beneficial effects in rat studies with ischemia-reperfusion induced arrhythmias. Istaroxime-metabolite derivatives have shown superior properties in these models indicating their potential as promising therapeutics for the treatment of patients with ischemia needing improvement in cardiac function.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WINT:
- Windtree Therapeutics announces partnership with New Growth Advisors
- Windtree Therapeutics Reports Q3 2024 Financial Results
- Windtree Therapeutics reports Q3 EPS ($4.23) vs. ($15.47) last year
- Windtree Therapeutics Appoints Jed Latkin as New CEO
- Windtree Therapeutics announces CEO Fraser to retire, Latkin to succeed